These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Statistical considerations for the next generation of clinical trials. Wu W; Shi Q; Sargent DJ Semin Oncol; 2011 Aug; 38(4):598-604. PubMed ID: 21810519 [TBL] [Abstract][Full Text] [Related]
3. Novel designs and end points for phase II clinical trials. Adjei AA; Christian M; Ivy P Clin Cancer Res; 2009 Mar; 15(6):1866-72. PubMed ID: 19276272 [TBL] [Abstract][Full Text] [Related]
4. Phase II clinical trials in oncology: are we hitting the target? Ang MK; Tan SB; Lim WT Expert Rev Anticancer Ther; 2010 Mar; 10(3):427-38. PubMed ID: 20214523 [TBL] [Abstract][Full Text] [Related]
5. The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials. Calvert AH; Plummer R Clin Cancer Res; 2008 Jun; 14(12):3664-9. PubMed ID: 18559580 [TBL] [Abstract][Full Text] [Related]
6. Improving the design of phase II trials of cytostatic anticancer agents. Stone A; Wheeler C; Barge A Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736 [TBL] [Abstract][Full Text] [Related]
7. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III. El-Maraghi RH; Eisenhauer EA J Clin Oncol; 2008 Mar; 26(8):1346-54. PubMed ID: 18285606 [TBL] [Abstract][Full Text] [Related]
8. Methodological aspects of lung cancer clinical trials in the era of targeted agents. Di Maio M; Gallo C; De Maio E; Morabito A; Piccirillo MC; Gridelli C; Perrone F Lung Cancer; 2010 Feb; 67(2):127-35. PubMed ID: 19875193 [TBL] [Abstract][Full Text] [Related]
9. The emperor's new clothes or the current practice of clinical trials for multiple myeloma in the USA. Ballester O Cancer Invest; 2008 Jun; 26(5):445-7. PubMed ID: 18568765 [TBL] [Abstract][Full Text] [Related]
10. Endpoints for agents that slow tumor growth. Yu RX; Holmgren E Contemp Clin Trials; 2007 Jan; 28(1):18-24. PubMed ID: 16829208 [TBL] [Abstract][Full Text] [Related]
11. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis. Suman VJ; Dueck A; Sargent DJ Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764 [No Abstract] [Full Text] [Related]
12. A strategic framework for novel drug development in multiple myeloma. Anderson KC; Hannah AL; Pazdur R; Farrell AT Br J Haematol; 2007 Jul; 138(2):153-9. PubMed ID: 17593022 [No Abstract] [Full Text] [Related]
13. Design and endpoints of clinical trials in hepatocellular carcinoma. Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ; J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802 [TBL] [Abstract][Full Text] [Related]
14. Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. Jiang W; Freidlin B; Simon R J Natl Cancer Inst; 2007 Jul; 99(13):1036-43. PubMed ID: 17596577 [TBL] [Abstract][Full Text] [Related]
15. New drugs in multiple myeloma. Berenson JR; Yellin O Curr Opin Support Palliat Care; 2008 Sep; 2(3):204-10. PubMed ID: 18685422 [TBL] [Abstract][Full Text] [Related]